EPISODE · Aug 4, 2016 · 11 MIN
J-Alex Trial: Should Alecensa Replace Xalkori as First-Line ALK Therapy?
from GRACEcast · host cancerGRACE Meetings
GRACE is happy to present the 5th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the J-Alex trial and whether Alecensa should replace Xalkori as First-Line ALK Therapy.
Embed this episode
NOW PLAYING
J-Alex Trial: Should Alecensa Replace Xalkori as First-Line ALK Therapy?
No transcript for this episode yet
Similar Episodes
No similar episodes found.